Navigation Links
Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp.
Date:4/14/2011

ALEXANDRIA, Va., April 14, 2011 /PRNewswire/ -- Oxford Finance Corporation (Oxford), a subsidiary of Sumitomo Corporation, today announced that it closed a $2 million equipment loan with Synta Pharmaceuticals Corp.  The funds will finance laboratory equipment used to manufacture compounds for use in Synta's ongoing clinical trials in the areas of oncology and chronic inflammatory diseases.

"Synta Pharmaceuticals has a diverse drug pipeline, including two leading cancer drugs currently in Phase 2 development in a broad range of indications," said Chad D. Norman, managing director for Oxford Finance.  "Oxford is very pleased to provide capital to support the development and delivery of Synta's novel pharmaceutical products."

About Oxford Finance Corporation

A subsidiary of Sumitomo Corporation, Oxford is a specialty finance firm providing senior secured loans to public and private life science and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $1.5 billion in loans, with lines of credit ranging from $500 thousand to $40 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in California, Massachusetts and North Carolina. For more information visit www.oxfordfinance.com.

About Synta Pharmaceuticals Corp.

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. For more information, please visit www.syntapharma.com.


'/>"/>
SOURCE Oxford Finance Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oxford BioTherapeutics Licenses BioWas POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer
2. ICAP Ocean Tomo Announces Four Patent Sets From Oxford Instruments - Each Represents an Important Advancement in Technology
3. Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation
4. Oxford Finance Corporation Hires Debbie Baker to Support Life Science Business Development in Western North America
5. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
6. Oxford Finance Corporation and United Orthopedic Group, Inc. Close $20 Million Credit Facility
7. Oxford Finance Corporation Facilitates Entry for Reata Pharmaceuticals into Asian Markets
8. Oxford Finance Corporation Closes $25 Million Credit Facility with EUSA Pharma
9. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
10. Cumberland Pharmaceuticals Appoints Rick S. Greene as Vice President, Finance & Accounting
11. Huifeng Bio-Pharmaceutical Technology Announces New Senior Vice President of Finance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... BOSTON , April 20, 2017   ZappRx, Inc ... the specialty drug prescribing process, today announced it closed $25 ... Fund, a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included ... A round in 2014, and GV (formerly Google ...
(Date:4/20/2017)... , April 20, 2017 ... platform, the first non-viral gene expression technology that enables ... the eye to address a wide range of ophthalmic ... Medicines and Healthcare products Regulatory Agency (MHRA) to advance ... ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... 24, 2017 , ... Today, Bright Pink , a national non-profit organization focusing on the ... CEO. , Bright Pink is proud to announce Katie Thiede as their new Chief ... new role as Chairman of the Board and launched a national search to find ...
(Date:4/24/2017)... ... April 24, 2017 , ... The John P. McGovern Museum of ... anyone, anywhere to track their cognitive health, and share results with their physicians. Members ... health on the museum's website. , BrainCheck founder, Dr. David Eagleman, formerly at Baylor ...
(Date:4/24/2017)... ... April 24, 2017 , ... Salus Telehealth, ... the company’s VideoMedicine mobile platform has launched Quick Care, a new service offering ... Quick Care provides patients with the option to request and begin a consultation ...
(Date:4/24/2017)... ... April 24, 2017 , ... MAP Health Management announced ... in people with addiction who are served by MAP’s patient engagement ecosystem. Lief ... that monitors heart and breath rates to identify anxiety levels and can provide ...
(Date:4/24/2017)... ... April 24, 2017 , ... Come to PAINWeekEnd (PWE) Tampa on May 20 ... an educational and exciting 2-day program. , An attendee at a recent PAINWeekEnd ... approach patients” about the course entitled Ain't Misbehavin': Decreasing and Managing Pain Patient Aberrant ...
Breaking Medicine News(10 mins):